HC Wainwright Reiterates Buy Rating for Silence Therapeutics (NASDAQ:SLN)

HC Wainwright restated their buy rating on shares of Silence Therapeutics (NASDAQ:SLN) in a report published on Thursday morning, Benzinga reports. They currently have a $75.00 target price on the stock.

Several other equities research analysts have also commented on the stock. Chardan Capital reaffirmed a buy rating and set a $42.00 price target on shares of Silence Therapeutics in a research report on Friday, May 17th. Morgan Stanley reiterated an overweight rating and issued a $45.00 price target on shares of Silence Therapeutics in a research report on Monday, April 22nd.

Silence Therapeutics Stock Performance

NASDAQ SLN opened at $19.00 on Thursday. The stock has a 50-day moving average of $21.15 and a 200 day moving average of $20.99. The company has a market capitalization of $568.67 million, a price-to-earnings ratio of -16.38 and a beta of 1.34. Silence Therapeutics has a one year low of $4.84 and a one year high of $27.72.

Silence Therapeutics (NASDAQ:SLN) last issued its quarterly earnings data on Thursday, May 16th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.18. Silence Therapeutics had a negative return on equity of 79.90% and a negative net margin of 131.44%. The company had revenue of $15.73 million during the quarter, compared to analyst estimates of $4.53 million. On average, equities analysts predict that Silence Therapeutics will post -1.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Silence Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SLN. SG Americas Securities LLC bought a new position in shares of Silence Therapeutics in the fourth quarter worth approximately $110,000. Parkman Healthcare Partners LLC boosted its holdings in Silence Therapeutics by 20.8% in the 4th quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock worth $4,046,000 after buying an additional 40,063 shares during the period. Vivo Capital LLC bought a new position in Silence Therapeutics in the 4th quarter worth $8,862,000. Lynx1 Capital Management LP increased its stake in Silence Therapeutics by 123.4% in the 1st quarter. Lynx1 Capital Management LP now owns 526,642 shares of the company’s stock worth $11,375,000 after buying an additional 290,855 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new stake in Silence Therapeutics during the first quarter valued at about $13,575,000. Institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.